ABU DHABI - The Abu Dhabi Stem Cells Center (ADSCC), in collaboration with Sheikh Khalifa Medical City, has treated its first Emirati patient through the Abu Dhabi Bone Marrow Transplant program (AD-BMT). The transplant was performed in Abu Dhabi, and the patient is recovering well at home.
The AD-BMT program was established by ADSCC in August 2020 and has been treating patients since its inception in collaboration with Sheikh Khalifa Medical City. The AD-BMT program relies on stem cell therapy to treat patients with hematological and oncological illnesses, including bone marrow transplantation, which is an established stem cell-based treatment for a number of blood malignancies. These include multiple myeloma, plasma cell leukemia, large diffuse B-cell lymphoma, and Hodgkin lymphoma, as well as autoimmune diseases and benign hematological conditions such as thalassemia, among others.
In less than a year, eight patients with different types of blood malignancies have been treated. AbdelRahman Al Jaberi, the eighth patient in question, said: “I wasn’t aware that stem cell therapy was available in the UAE, but I’m grateful to God and to our leader, His Highness Sheikh Mohamed Bin Zayed – may he have a long life – for supporting the center so that I don’t have to travel and can recover at home in Abu Dhabi amongst my family.”
He continued, “With COVID-19, there’s a risk from travel and the time demands of quarantine. Thankfully, I don’t have to worry about that. With my family and friends standing by me, I feel a much-needed dose of positive energy to continue with the treatment. Thank God for that.”
Dr. Fatema Al Kaabi, Executive Director of the Abu Dhabi Bone Marrow Transplant program and lead physician during Al Jaberi’s treatment, said: “We are almost 50 years old as a country and are treating cancer patients using an internationally approved treatment method with curative intentions. We are aiming to incorporate smart immunotherapies and cell engineering methodologies to fight cancers in the UAE and the region.”
Dr. Yendry Ventura, Specialist in Immunology and General Manager of ADSCC, said, "As immunologists, we strive to identify innovative methods to treat conditions that are known to be challenging to cure. Using stem cell therapy in the form of bone marrow transplants is one of the most well-known and established methods to treat various conditions of blood malignancies.”
ADSCC was founded with the primary objective of meeting growing domestic and regional demand for advanced medical services and the most innovative treatments in the UAE. ADSCC is committed to ensuring the Abu Dhabi Bone Marrow Transplant program meets the highest standards of quality and patient satisfaction at every step in the process, including treatment, aftercare, and follow-up for clinical BMT personnel, patients, and their families.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
